Payment overview · 2025
General Payments
$925.49
45 reported records · 16 companies
Healthcare provider profile · identity verified
Joshua Wade Mccarthy, MD
Allopathic & Osteopathic Physicians|Family Medicine · WAYCROSS, GA · NPI 1578827408
Verified facts
What the public records show
CMS Open Payments records show Joshua Wade Mccarthy, MD received $925.49 in general payments during 2025 across 45 reported records.
Amgen Inc. accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 438 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $158.53 | 17.1% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $152.80 | 16.5% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $95.25 | 10.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $76.91 | 8.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.90 | 6.6% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $57.53 | 6.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.98 | 6.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $54.07 | 5.8% | 2 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $48.95 | 5.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.48 | 3.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.66 | 3.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.70 | 3.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.47 | 2.1% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.34 | 1.9% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $16.75 | 1.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.17 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $925.49 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $126.36 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $126.36 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $106.94 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $106.94 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $95.25 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $76.91 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.90 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.90 | 3 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $57.53 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $54.07 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $51.59 | 3 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $48.95 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.48 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.66 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $28.70 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $26.44 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 438 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 226 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 99 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 107 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
122 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
226 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
23 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
107 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
226 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
99 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
438 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 845 | 85 |
| Gabapentin | Gabapentin | 719 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 597 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 578 | 112 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 536 | 62 |
| Furosemide | Furosemide | 508 | 66 |
| Escitalopram Oxalate | Escitalopram Oxalate | 482 | 42 |
| Eliquis | Apixaban | 438 | 37 |
| Potassium Chloride | Potassium Chloride | 438 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 419 | 35 |
| Lisinopril | Lisinopril | 409 | 75 |
| Omeprazole | Omeprazole | 404 | 54 |
| Famotidine | Famotidine | 382 | 38 |
| Metformin Hcl | Metformin Hcl | 370 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 368 | 77 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 367 | 86 |
| Losartan Potassium | Losartan Potassium | 354 | 49 |
| Trazodone Hcl | Trazodone Hcl | 352 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 330 | 51 |
| Carvedilol | Carvedilol | 298 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 297 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 292 | 37 |
| Simvastatin | Simvastatin | 274 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 271 | 30 |
| Memantine Hcl | Memantine Hcl | 265 | 12 |
| Divalproex Sodium | Divalproex Sodium | 253 | suppressed |
| Jardiance | Empagliflozin | 226 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 225 | 53 |
| Montelukast Sodium | Montelukast Sodium | 220 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 220 | 12 |
| Sertraline Hcl | Sertraline Hcl | 217 | 21 |
| Tramadol Hcl | Tramadol Hcl | 213 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 210 | 53 |
| Tizanidine Hcl | Tizanidine Hcl | 210 | 23 |
| Spironolactone | Spironolactone | 189 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 181 | 11 |
| Januvia | Sitagliptin Phosphate | 171 | 11 |
| Prednisone | Prednisone | 165 | 67 |
| Myrbetriq | Mirabegron | 158 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 42 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 154 | 11 |
| Atenolol | Atenolol | 148 | suppressed |
| Allopurinol | Allopurinol | 146 | 29 |
| Donepezil Hcl | Donepezil Hcl | 143 | 17 |
| Pregabalin | Pregabalin | 143 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 142 | 17 |
| Mirtazapine | Mirtazapine | 137 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 136 | 20 |
| Buspirone Hcl | Buspirone Hcl | 135 | suppressed |
| Alprazolam | Alprazolam | 124 | 28 |
| Farxiga | Dapagliflozin Propanediol | 122 | 12 |
| Glipizide | Glipizide | 118 | 18 |
| Clonazepam | Clonazepam | 110 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 107 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 107 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 37 |
| Lorazepam | Lorazepam | 100 | 24 |
| Meloxicam | Meloxicam | 100 | 30 |
| Ozempic | Semaglutide | 99 | 28 |
| Doxepin Hcl | Doxepin Hcl | 98 | suppressed |
| Ezetimibe | Ezetimibe | 94 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 92 | 20 |
| Bumetanide | Bumetanide | 90 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 90 | 60 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 17 |
| Diltiazem Hcl | Diltiazem Hcl | 88 | suppressed |
| Levetiracetam | Levetiracetam | 87 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 82 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 78 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 74 | suppressed |
| Olanzapine | Olanzapine | 73 | suppressed |
| Risperidone | Risperidone | 73 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 17 |
| Rivastigmine | Rivastigmine Tartrate | 71 | suppressed |
| Bupropion Xl | Bupropion Hcl | 69 | 11 |
| Haloperidol | Haloperidol | 69 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 68 | suppressed |
| Trulicity | Dulaglutide | 68 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 64 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | suppressed |
| Glimepiride | Glimepiride | 60 | 15 |
| Colchicine | Colchicine | 59 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 59 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 59 | 12 |
| Ramipril | Ramipril | 58 | suppressed |
| Cefdinir | Cefdinir | 57 | 42 |
| Tradjenta | Linagliptin | 56 | suppressed |
| Valsartan | Valsartan | 56 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 54 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 16 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 53 | suppressed |
| Linzess | Linaclotide | 53 | 14 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 53 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 52 | suppressed |
| Digoxin | Digoxin | 52 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 49 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 19 |
| Rivastigmine | Rivastigmine | 49 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 46 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 11 |
| Cephalexin | Cephalexin | 43 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 42 | suppressed |
| Methocarbamol | Methocarbamol | 41 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 17 |
| Savella | Milnacipran Hcl | 41 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 40 | 18 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 38 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 37 | suppressed |
| Temazepam | Temazepam | 37 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 36 | suppressed |
| Roflumilast | Roflumilast | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 25 |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Novolog Flexpen | Insulin Aspart | 34 | suppressed |
| Acyclovir | Acyclovir | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 11 |
| Baclofen | Baclofen | 32 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 25 |
| Albuterol Sulfate | Albuterol Sulfate | 30 | 21 |
| Celecoxib | Celecoxib | 30 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 15 |
| Indomethacin | Indomethacin | 30 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | 12 |
| Ketoconazole | Ketoconazole | 28 | 12 |
| Ondansetron Odt | Ondansetron | 28 | 14 |
| Verapamil Sr | Verapamil Hcl | 28 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 25 | 13 |
| Dexamethasone | Dexamethasone | 24 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 24 | 14 |
| Latanoprost | Latanoprost | 24 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 16 |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Scopolamine | Scopolamine | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Progesterone | Progesterone, Micronized | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 19 | suppressed |
| Xtampza Er | Oxycodone Myristate | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 13 |
| Enulose | Lactulose | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Mirabegron Er | Mirabegron | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 14 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | 11 |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $925.49 · 45 records | Amgen Inc. | AIRSUPRA, CAPLYTA, Cologuard Collection Kit, ELIQUIS, EVENITY, FANAPT, General - Pain Management, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PURAPLY WOUND MATRIX, Quviviq, REPATHA, TRELEGY ELLIPTA, VRAYLAR, Wegovy, XHANCE, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error